Literature DB >> 4256145

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).

F J Ansfield, G Ramirez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4256145

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  16 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Antitumor cell and antimetabolic effects of 5-ethyl-2'-deoxyuridine and 5'-substituted 5-ethyl-2'-deoxyuridine derivatives.

Authors:  J Balzarini; E De Clercq; G Kiefer; K Keppeler; A Buchele
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 3.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

4.  Experimental herpes simplex virus type 1 encephalitis: treatment with 5-trifluoromethyl-2'-deoxyuridine.

Authors:  D W Clough; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

5.  Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors:  S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Authors:  Michael J Overman; Gauri Varadhachary; Scott Kopetz; Melanie B Thomas; Masakazu Fukushima; Keizo Kuwata; Akira Mita; Robert A Wolff; Paulo M Hoff; Henry Xiong; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2008-06-05       Impact factor: 3.850

7.  Activity of trifluorothymidine against cytomegalovirus.

Authors:  J R Wingard; R K Stuart; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

8.  Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.

Authors:  S Takeda; K Wierzba; J Yamashita; H Matsumoto; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

10.  Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

Authors:  T Doi; A Ohtsu; T Yoshino; N Boku; Y Onozawa; A Fukutomi; S Hironaka; W Koizumi; T Sasaki
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.